Get started
Connect Biopharma Holdings LimitedConnect Biopharma Holdings LimitedConnect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CNTB trade ideas

CNTB - long - catalyst playConnect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174. This is not a financial advice! Upcoming catalyst on 31st. of March I would wait for a pullback to the 1. 20 level for a better entry Keep an eye on 1.77 level - needs to get broken for a further upmove. SL under 1.10 TP approx. 2.8 Most info on the chart. Trade carefully!
NASDAQ:CNTBLong
by meitshels_smell_trades
A Stock on the Brink of Breakthrough?Introduction: In the ever-evolving landscape of biopharmaceuticals, Connect Biopharma Holdings Limited (NASDAQ: CNTB) emerges as a beacon of potential, navigating through the complexities of drug development with promising advancements and strategic maneuvers. This analysis dives into the core of CNTB's recent activities, financial health, and future prospects, shedding light on why this stock might just be the next big thing in the biotech sphere. A Strategic Pivot: Key Developments and Milestones Connect Biopharma, with its focus on developing novel therapies for autoimmune diseases and inflammation, has recently made headlines with significant strategic developments. The company's lead product candidate, rademikibart, is currently under pivotal trials for atopic dermatitis (AD) in China, with an NDA submission expected by Q1’24 and potential approval as early as 2025. Moreover, their global Phase 2 trial for rademikibart in asthma is on track, with last patient visits expected in October 2023 and topline readouts anticipated in Q4’23​​. Financial Health: A Closer Look at the Numbers The financial results for the first half of 2023 reveal a company steadfast in its research and development endeavors, albeit with a keen eye on sustainability. With cash, cash equivalents, and short-term investments of USD 131.6 million as of June 30, 2023, Connect Biopharma appears well-capitalized to support its operations into at least 2026​​. Notably, a decrease in R&D expenses and administrative costs compared to the previous year underscores a strategic allocation of resources towards its most promising projects​​. Market Position and Technical Outlook As of recent trading sessions, CNTB stock demonstrated a notable uptick, trading at $1.30 with a 7.44% increase​​. This movement, coupled with a consensus rating of "Buy" from analysts and a projected upside of over 500%, positions CNTB as a stock with significant growth potential​​. The company's stock price range over the past 52 weeks — from $0.5350 to $2.8400 — further highlights its volatility and the opportunity for substantial gains​​. Conclusion: A Future Ripe with Opportunity Connect Biopharma stands at the forefront of breakthrough treatments for autoimmune diseases, backed by a solid financial foundation and strategic clinical advancements. With key milestones on the horizon and a favorable market outlook, CNTB represents a compelling opportunity for investors keen on the biopharmaceutical sector. As the company progresses towards its pivotal trial outcomes and regulatory submissions, the potential for significant value creation looms large, making CNTB a stock to watch closely in the coming months. --------------- NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
NASDAQ:CNTBLong
by olimchik
Long term holding, hedge fund manipulation detectedIt is part of the sell-out part from the RA Capital group. Derek DiRocco from RA Capital Group stepped down from the Board and in that part, this led to the SEC filing showing RA just sold 1 million shares (label in red circle). The RA capital group still has a lot left to sell but it seems they are withdrawing from the company. The next guy coming up is Kan Chen who is from Qiming Venture. The Qiming Venture has a similar size compared to RA Capital but it shows the influence of China over the CNTB company decision. The CNTB initially was thought to be focused on the China market with their CBP-201, but after the Simcere contract, it seems that they would be the spear targeting the US market running under the China influence. This does not sit well with many US investing companies which led to mass selling from the US Venture Capital company. Still, besides the complicated politics, CNTB is a good buy for under $7 because it has good results and a very bright future if its products hit the market after phase 3. It is a long-term holding (5 years). Eventually, after their products make a profit and hit the market, their market cap would be huge, unless they file bankruptcy due to poor decisions from voting or anything else. That is often not how Chinese companies run so it would be a long-term investment. I think CNTB is among the top 20 biotech stocks for startups. This is not financial advice and please be responsible for your own investment decision!
NASDAQ:CNTBLong
by Hamahamieng
Potential break through $3 scenario for CNTBAfter the good news this morning, the CNTB just got a big dip from one of the whales with weak resistance buyback force resulting in a sum of 3mil shares exchanged between buy and sale leading to a current ~$1.4. However, I noticed a similar pattern around October time where a bullish push for $1.2 and a big dip after that down to $0.79. This dip is almost 36% dip while we are experiencing $1.4 from $2.89 which is dip %51. This dip is much larger than the previous dip with potentially an uptrend bullish run for CNTB for the next 1 month run to above $3. This is a bullish scenario for the CNTB and hopefully, we will see the result of the fight between the bull and the bear! This is not financial advice but my update views on CNTB's position after recent good news!
NASDAQ:CNTBLong
by Hamahamieng
New long hold for good startup Biopharma companyWithout looking at the news, the CNTB should have gone down to get more air and stay around the $1.6 zone to be attractive. However, the new news regarding Simcere obtained the exclusive deal with CNTB regarding phase 3 drug rademikibart providing CNTB immediate big funding ($21M-$121M). This may signal a very bullish run if the market receives this news as excitement. The CNTB is still able to develop and commercialize rademikibart elsewhere aside from the greater China region (China, Hong Kong, Taiwan, Macau). We detect here a Cup and handle patterns and suspect there would be a breakthrough ceiling at $2.83 after rallying around $2.5. This is not financial advice but my view on CNTB at the current time!
NASDAQ:CNTBLong
by Haizsama
1